In this retrospective study, we assessed whether the HER2 IHC score could accurately predict the efficacy of neoadjuvant treatment in HER2-positive breast cancers, such as total pathological complete response (tpCR), breast pathological complete response (bopper), and axillary pathological complete response (apCR). This evidence concerns the gene ERBB2 and breast carcinoma.